Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
Patent Information
- Application Number
- HK62026127040
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-19
- Filing Date
- 2026-08-04
- Publication Date
- 2026-09-11
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480064936.2 (22) Application Date 2024.10.18 (30) Priority Data 202341071495 2023.10.19 IN (85) PCT International Application Entering National Phase Date 2026.04.09 (86) PCT International Application Application Data PCT / IB2024 / 060262 2024.10.18 (87) PCT International Application Publication Data WO2025 / 083630 EN 2025.04.24 (71) Applicant: Suwen Life Sciences Ltd. Address: India (72) Inventor: Ramakrishna Niroji Anil Kabari Hind Abdul Rashid Muhammad Rajesh Kumar Baidanjislawanti Manchinilanara Singha Tirumararajavan Chodli Parachara Ram Kumar Subramaniam Anvenkatswaru Justi (74) Patent Agency: Beijing J&J Intellectual Property Agency Co., Ltd. 11227 Patent Attorney: Zhang Fuyu (51) Int.Cl. C07D 471 / 12 (2006.01) C07D 487 / 12 (2006.01) A61P 25 / 18 (2006.01) A61K 31 / 4353 (2006.01) A61K 31 / 495 (2006.01) (54) Invention Title: Heteroaromatic Compounds as Muscarinic M4 Receptor Positive Allosteric Modulators (M4 PAM) (57) Abstract: This invention relates to heteroaromatic compounds of formula (I) as muscarinic M4 receptor positive allosteric modulators (M4 PAM), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising such compounds, chemical methods for preparing such compounds, and the use of such compounds in the treatment of mental disorders and / or neurological disorders. Claims 5 pages, Description 50 pages, CN 122003415 A 2026.05.08 CN 1 22 00 34 15 A 1. A compound of formula (I), or an isotopic form or stereoisomer or pharmaceutically acceptable salt thereof, wherein each may be a single bond or a double bond independently; X1 is N or C, provided that R1 is absent when X1 is N; X2, X3, X4, X5 and X6 are independently selected from N or C, provided that at least one of X2, X3, X4, X5 and X6 is C; and provided that R2, R3 or R4 is absent when X4, X5 or X6 is N; R1, when present, is selected from hydrogen, halogen, cyano, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl or C1-C4 alkoxyalkyl;R2, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl; R3, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl; R4, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl; R5, when present, is selected from hydrogen, halogen, -NH2, -NHCH3, C1-C4 alkyl, C1-C4 alkoxyalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl; R6 is independently selected from hydrogen or C1-C4 alkyl; A is selected from 3- to 7-membered cycloalkyl or 4- to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, halogen, deuterium, cyano, -OC1-C4 alkyl and C1-C4 haloalkyl; B is selected from 6- to 10-membered aryl or 5- to 10-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, -NH2, NHCH3, C1-C4 alkyl, C1-C4 haloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl and C3-C7 cycloalkyl; and n is an integer from 0 to 3. 2. The compound of formula (I) according to the foregoing embodiments, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, wherein the compound is selected from: 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone; 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl- Azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-ethyl ketone; 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-4-yl-azacyclobutane-3-yl)-ethyl ketone;2-[1-(2-chloro-5-methoxy-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-acetone; (2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-methyl ketone; (2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-(1-pyridin-3-yl-pyrrolidine-3(R)-yl)-methyl ketone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-(1-pyridin-4-yl-azacyclobutane-3-yl)-acetone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-acetone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(3-trifluoromethyl-phenyl)-azacyclobutane-3-yl]-acetone; (4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(3-trifluoromethyl-phenyl)-azacyclobutane-3-yl]-acetone; (4,7-dimethyl-1,3-dihydro-2,6... ,8a-triaza-asymmetric indahedron-2-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-methyl ketone; 1-(4-methyl-1,3-dihydro-2,6,8a-triaza-asymmetric indahedron-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 1-(4-methyl-1,3-dihydro-2,6,8a-triaza-asymmetric indahedron-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; 1-(4-methyl-1,3-dihydro-2,7- ,8a-triaza-asymmetric indane-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone;1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-acetone; 1-(4,5-dimethyl-6,8-dihydro-1,2,3a)-1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-acetone; ,7-Tetraaza-asymmetric indahedron-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; 1-(4,5-dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indahedron-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-ethyl ketone; Claims 2 / 5 pages 3 CN 122003415 A 1-(4,5-dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indahedron-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(3,4,5-trimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-acetone; 1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-2-(1- Pyridin-3-yl-azacyclobutane-3-yl)-acetone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; 2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; 2-(1-pyridin-3-yl-azacyclobutane-3-yl)-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,[2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; 1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl- [Pyridin-3-yl]-azacyclobutane-3-yl]-acetone; 1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-acetone; (4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-methyl ketone; 1-(5-methyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone; 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;1-(2,5-dimethyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4-methyl-1,3-dihydro-2,5,6,8a-tetraaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4-methyl-1,3-dihydro-2,5,6,8a-tetraaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 1-(1,5-dimethyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; or 1-(1,5-dimethyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone. 3. The compound of formula (I) according to claim 1 or claim 2, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, used as a positive allosteric modulator of muscarinic M4 receptor (M4 PAM). 4. A pharmaceutical composition comprising the compound of formula (I) according to claim 1 or claim 2, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, and a pharmaceutically acceptable excipient. 5. The pharmaceutical composition according to claim 4, for treating diseases or disorders mediated by muscarinic M4 receptors, wherein the disease or disorder is selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive impairments. 6. The compound of formula (I) according to claim 1 or claim 2, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, for treating diseases or disorders mediated by muscarinic M4 receptors, wherein the disease or disorder is selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive impairments. 7. The compound of claim 6, wherein the mental disorder is selected from anxiety, personality disorders, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, attention deficit / hyperactivity disorder (ADHD), psychosis, schizophrenia, substance use disorder, and psychotic disorders. 8. The compound of claim 6, wherein the neurological disease or disorder is selected from Alzheimer's disease, Rett syndrome, Huntington's disease, vascular dementia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).9. The compound of claim 6, wherein the cognitive impairment is selected from amnesia, dementia, amnesic disorder, dementia due to Alzheimer's disease, dementia due to HIV, dementia due to Huntington's disease, dementia due to Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, senile dementia, dementia associated with Down syndrome, dementia associated with Tourette syndrome, dementia associated with postmenopausal syndrome, Kreutzfeldt-Jacob dementia, substance-induced persistent dementia, Pick's disease dementia, Huntington's disease dementia, traumatic brain injury, prions, HIV-related neurocognitive impairment, mild cognitive impairment, and any other disease with cognitive symptoms. 10. The compound of claim 7, wherein the schizophrenia is selected from schizophrenic cognitive impairment, positive symptoms of schizophrenia, and / or negative symptoms of schizophrenia. 11. The compound of claim 7, wherein the psychotic disorder is selected from psychosis associated with Alzheimer's disease, psychosis associated with Parkinson's disease, psychotic depression, psychosis associated with stroke, psychosis associated with epilepsy, psychosis associated with multiple sclerosis, psychosis associated with traumatic brain injury, substance-induced persistent delirium, or any other disease with psychotic characteristics. 12. A compound of formula (II) or a pharmaceutically acceptable salt thereof: Claims 4 / 5 pages 5 CN 122003415 A Wherein, each may be a single bond or a double bond independently; X1 is selected from C or N; X2 is selected from C or N; X3 is selected from C or N; X4 is selected from C or N; X5 is selected from C or N; X6 is selected from C or N; provided that at least one of X1, X2, X3, X4, X5 and X6 is C; provided that when X1, X2, X3, X4, X5 or X6 is N, then R1, R2, R3 or R4 is absent; R1, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl or C4-C10 heterocyclic alkyl; R2, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl; R3, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C4 cycloalkyl, or C4-C10 heterocyclic alkyl; R4, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl; R5, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl; and R6 is selected from hydrogen or C1-C4 alkyl.13. The compound of formula (II) according to claim 12 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2 or CF3; wherein R2 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2 or CF3; wherein R3 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2 or CF3; wherein R4 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2 or CF3; wherein R5 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2, CF3 or CF3; and wherein R6 is selected from hydrogen, methyl or ethyl. Claims 5 / 5 Page 6 CN 122003415 A Heteroaromatic Compounds as Muscarinic M4 Receptor Positive Allosteric Modulators (M4 PAM) Technical Field
[0001] This invention relates to heteroaromatic compounds of formula (I) as muscarinic M4 receptor positive allosteric modulators (M4 PAM), or their isotopic forms, stereoisomers, or pharmaceutically acceptable salts. The invention also describes methods for preparing such compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds in the treatment of mental disorders and / or neurological disorders. Background Art
[0002] Currently, available pharmaceutical treatments for mental disorders and / or neurological disorders such as schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, and depression show modest improvements but have dose-limiting side effects, leading to non-compliance and partial responses.
[0003] Targeting muscarinic acetylcholine receptors (mAChRs) is a promising approach for treating mental disorders and / or neurological disorders because it provides new and improved drug options. mAChRs are G protein-coupled receptors (GPCRs) that are widely expressed throughout the body. To date, five subtypes, designated M1 to M5, have been identified that respond to the endogenous neurotransmitter acetylcholine (ACh). They play key roles in regulating the activity of many important functions of the central and peripheral nervous systems. The M1, M3, and M5 receptor subtypes are generally coupled to the G protein Gq / G11, while the M2 and M4 receptor subtypes are primarily coupled to the Gi / G0 protein (Wess et al., 1996, Crit Rev Neurobiol.;10(1):69-99; Langmead et al., 2008,Pharmacol Ther.; 117(2):232-243).
[0004] The M4 mAChR subtype has important therapeutic significance because it is expressed in regions of the brain rich in dopamine and dopamine receptors, where it regulates dopaminergic neurons associated with cognition, schizophrenia, psychosis and addiction (Kentaro et al., 2018, Chem. Pharm. Bull. 66(1), 37-44; Daniel et al., 2019, Drug Discov Today;24(12):2307-2314).
[0005] Xanomeline is an M1 / M4 preferred mAChR agonist that has been shown to significantly reduce behavioral symptoms in patients with Alzheimer's disease (Bodick et al., 1997, Arch Neurol.;54(4):465-73), but gastrointestinal side effects have led to a high drop-out rate in clinical trials. In an independent study, zenomeprazole showed efficacy against both positive and negative symptoms of schizophrenia (Shekhar et al., 2008, Am J Psychiatry;165(8): 1033-9). zenomeprazole also showed antipsychotic-like activity in various preclinical behavioral models (Mirza et al., 2003, CNS Drug Rev.;9(2):159-86). Subsequent studies showed that the antipsychotic-like effects of zenomeprazole were absent in M4-KO mice (Woolley et al., 2009 Eur J Pharmacol;603(1-3):147-9). High conservation among muscarinic receptor subtypes at their ortho-acetylcholine ligand binding sites makes it difficult to identify muscarinic subtype-selective agonists. To circumvent the issues of agonist selectivity and safety, an alternative approach is to develop selective muscarinic M4 receptor PAMs that act on less conserved allosteric binding sites.
[0006] In this regard, many muscarinic M4 receptor PAMs have been described in the literature, exhibiting cognitive enhancement and antipsychotic-like activities. For example, VU0467154 showed antipsychotic-like activity in rodent assays predicting antipsychotic effects (Gould et al., 2018, Neuropharmacology;128:492-502). Additionally, muscarinic M4 receptor PAMs have shown cognitive benefits in rodent models of learning and memory (Bubser et al., 2014 ACS Chem Neurosci.;5(10): 920-42).
[0007] Patent publications WO2018 / 002760, WO2018 / 234953, WO2021 / 099527, WO2023 / 064584, and US20180028501 disclose compounds as muscarinic M4 receptor PAMs. Although several muscarinic M4 receptor PAMs have been disclosed in the literature to date, no muscarinic M4 receptor PAM compounds are commercially available for the treatment of M4-mediated diseases or disorders, such as schizophrenia, Alzheimer's disease, psychosis, Parkinson's disease, pain, addiction, and Huntington's disease. Therefore, there remains an unmet need for developing new and more effective muscarinic M4 receptor PAMs for the treatment of disorders affected by muscarinic M4 receptors.
[0008] This invention discloses novel compounds as muscarinic M4 receptor PAMs with desired characteristics. The compounds of this invention exhibit potent affinity, selectivity, acceptable pharmacokinetic properties, good brain penetration, and potency in animal models.
[0009] In a first aspect, the present invention relates to a compound of formula (I), or an isotopic form or stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0010]
[0011] wherein,
[0012] each may be a single bond or a double bond independently;
[0013] X1 is N or C, provided that R1 is absent when X1 is N;
[0014] X2, X3, X4, X5 and X6 are independently selected from N or C, provided that at least one of X2, X3, X4, X5 and X6 is C; and provided that R2, R3 or R4 is absent when X4, X5 or X6 is N;
[0015] R1, when present, is selected from hydrogen, halogen, cyano, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl or C1-C4 alkoxyalkyl;
[0016] R2, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0017] R3, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0018] R4, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0019] R5 is selected from hydrogen, halogen, -NH2, -NHCH3, C1-C4 alkyl, C1-C4 alkoxyalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl;
[0020] R6 is independently selected from hydrogen or C1-C4 alkyl;
[0021] A is selected from 3 to 7-membered cycloalkyl or 4 to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, halogen, deuterium, cyano, -OC1-C4 alkyl and C1-C4 haloalkyl;
[0022] B is selected from 6 to 10-membered aryl or 5 to 10-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, -NH2, NHCH3, C1-C4 alkyl, C1-C4 haloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl and C3-C7 cycloalkyl; and
[0023] n is an integer from 0 to 3.
[0024] In another aspect, the present invention relates to a method for preparing a compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof.
[0025] In another aspect, the present invention relates to a compound of formula (I), or its isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, used as a positive allosteric modulator of muscarinic M4 receptors.
[0026] In another aspect, the present invention relates to a method for treating muscarinic M4 receptor-mediated diseases or disorders, the method comprising administering to a patient in need a therapeutically effective amount of a compound of formula (I), or its isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof.
[0027] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound of formula (I), or its isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Detailed Description
[0028] This document discloses muscarinic M4 receptor PAM, methods for preparing such compounds, pharmaceutical compositions comprising such compounds, and methods for treating muscarinic M4 receptor-mediated diseases or disorders such as mental disorders and / or neurological disorders.
[0029] Unless otherwise stated, the following terms used in this specification and claims have the following meanings:
[0030] The term “C1-C4 alkyl” as used herein refers to a branched or straight-chain aliphatic hydrocarbon containing 1 to 4 carbon atoms. Some examples of C1-C4 alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.
[0031] The term “C1-C4 haloalkyl” as used herein refers to a C1-C4 alkyl as defined above, wherein one or more hydrogen atoms of the same or different carbon atoms are substituted by halogen atoms. Some examples of C1-C4 haloalkyl include, but are not limited to, fluoromethyl, 2-fluoroethyl, difluoromethyl, and trifluoromethyl.
[0032] As used herein, the term “-OC1-C4 alkyl” refers to a C1-C4 alkyl group as defined above, which is partially attached to the parent molecule by an oxygen atom. Some examples of -OC1-C4 alkyl groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, and butoxy.
[0033] As used herein, the term “OC1-C4 haloalkyl” refers to a C1-C4 haloalkyl group as defined above, bonded to an oxygen atom. Some examples of OC1-C4 haloalkyl groups include, but are not limited to, -OCH2F, -OCHF2, and -OCF3.
[0034] As used herein, the term “C1-C4 alkoxyalkyl” refers to a C1-C4 alkyl group as defined above, wherein one or more hydrogen atoms of the same or different carbon atoms are substituted by -OC1-C4 alkyl. Some examples of C1-C4 alkoxyalkyl groups include, but are not limited to, methoxymethyl, ethoxymethyl, propoxymethyl, and butoxymethyl.
[0035] As used herein, the phrase “3- to 7-membered cycloalkyl or C3-C7 cycloalkyl” refers to a saturated monocyclic hydrocarbon ring containing 3 to 7 carbon atoms. Some examples of C3-C7 cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
[0036] As used herein, the term “halogen” refers to fluorine, chlorine, bromine, or iodine. Preferably, the halogen is fluorine, chlorine, or bromine.
[0037] The phrase “4 to 10-membered heterocyclic alkyl or C4-C10 heterocyclic alkyl” as used herein refers to a heterocyclic alkyl substituent containing a total of 4 to 10 ring atoms, wherein at least one ring atom is a heteroatom selected from nitrogen, oxygen, or sulfur. Some examples of 4 to 10-membered heterocyclic alkyl groups include, but are not limited to, aza-butanediol, pyrrolidiol, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydropyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, aza-heptane, and 1,4-oxaza-heptane.
[0038] The phrase “6 to 10-membered aryl or C6-C10 aryl” as used herein includes, but is not limited to, all-carbon monocyclic aryl or fused-ring polycyclic aryl groups having a conjugated π-electron system containing 6 to 10 carbon atoms. Some examples of 6- to 10-membered aryl groups include, but are not limited to, phenyl or naphthyl.
[0039] The phrase “5- to 10-membered heteroaryl or C5-C10 heteroaryl” as used herein refers to a 5-, 6-, 7-, 8-, 9-, or 10-membered aromatic heterocyclic ring, including monocyclic and bicyclic ring systems, wherein at least one carbon atom of one or two rings is independently replaced by a heteroatom selected from oxygen, nitrogen, or sulfur, or at least two carbon atoms of one or two rings are independently replaced by a heteroatom selected from nitrogen, oxygen, and sulfur. Some non-limiting examples of 5- to 10-membered heteroaryl groups include 6-membered ring substituents, such as pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl; 5-membered heteroaryl groups, such as triazolyl, imidazolyl, furanyl, isozolyl, isothiazolyl, 1,2,3-diazolyl, 1,2,4-diazolyl, 1,2,5-diazolyl or 1,3,4-diazolyl, azole, thiophene, thiazolyl, thiadiazolyl, isothiazolyl, and pyrazolyl; and 6 / 5-membered fused-ring substituents, such as indolyl, inazolyl, benzofuranyl, benzimidazolyl, benzothiophene, and benzo[[...]]Diazolyl, benzothiazolyl, isobenzothiofuranyl, benzothiofuranyl, benzoisozolyl, benzodioxolyl, benzodioxolyl, furanopyridyl, purine, imidazopyridyl, imidazopyrimidyl, pyrrolopyridyl, pyrazolopyridyl, pyrazolopyrimidyl, thienopyridyl, triazolopyrimidyl, triazolopyridyl (e.g., [1,2,4]triazolo[1,5-a]pyridin-2-yl) and anthranilyl; and 6 / 6-membered fused ring substituents, such as quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, oxochromyl and 1,4-benzozinyl.
[0040] As used herein, the phrase “isotopic form” refers to a compound of formula (I) in which one or more atoms of the compound of formula (I) are substituted with their respective isotopes. Some examples of isotopes that may be incorporated into the compounds disclosed herein include, but are not limited to, isotopes of hydrogen such as 2H (deuterium) and 3H (tritium or T), isotopes of carbon such as 11C, 13C, and 14C, isotopes of nitrogen such as 13N and 15N, isotopes of oxygen such as 15O, 17O, and 18O, isotopes of chlorine such as 36Cl, isotopes of fluorine such as 18F, and isotopes of sulfur such as 35S. Substitution with heavier isotopes (e.g., replacing one or more key carbon-hydrogen bonds with carbon-deuterium bonds) may exhibit certain therapeutic advantages due to longer metabolic cycles (e.g., increased in vivo half-life or reduced dose requirements), improved safety, or greater efficacy, and may therefore be preferred in certain circumstances.
[0041] Representative examples of isotopic forms of compounds of formula (I) may include, but are not limited to, deuterated compounds of formula (I). The term “deuterated” as used herein, either by itself or in the context of modifying a compound or group, refers to the substitution of one or more hydrogen atoms bonded to a carbon atom with a deuterium atom. For example, in any applicable context, a compound of formula (I) may contain deuterium, deuterated alkyl, deuterated alkoxy, deuterated cycloalkyl, deuterated heterocyclic, deuterated aryl, deuterated heteroaryl, etc., in one or more of its various variables. The term “deuterated alkyl” refers to a -(C1-C4)-alkyl group as defined above, wherein at least one hydrogen atom bonded to a carbon atom is replaced by deuterium. In other words, in a deuterated alkyl group, at least one carbon atom is bonded to deuterium. In a deuterated alkyl group, a carbon atom may be bonded to more than one deuterium atom; more than one carbon atom in an alkyl group may also be bonded to deuterium. Similarly, the terms “deuterated” and “deuterated heterocyclic group,” “deuterated heteroaryl group,” “deuterated cycloalkyl group,” “deuterated aryl group,” and “deuterated alkoxy group” each refer to the corresponding chemical moiety wherein at least one carbon atom is bonded to deuterium.
[0042] The term “stereoisomer” as used herein refers to compounds of formula (I) with different spatial arrangements of atoms.Isomers. The compounds disclosed herein may exist as a single stereoisomer, racemate, and / or a mixture of enantiomers and / or diastereomers. All such pure stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention, page 4 / 50, 10 CN 122003415 A.
[0043] The phrase “medicinal salt” as used herein refers to a salt of an active compound of formula (I) and prepared by reaction with a suitable acid or base (depending on the specific substituents present on the compound described herein).
[0044] The phrase “therapeutic amount” is defined as an amount of the compound of the invention that (i) treats a particular disease, symptom, or disorder, (ii) eliminates one or more symptoms of a particular disease, symptom, or disorder, and / or (iii) delays the onset of one or more symptoms of a particular disease, symptom, or disorder described herein.
[0045] As used herein, the phrase “positive allosteric modulator of M4 receptor (PAM)” refers to a ligand that interacts with an allosteric site of the receptor to enhance the response produced by an endogenous ligand at the allosteric binding site. The compounds of the present invention are allosteric modulators of the M4 muscarinic acetylcholine receptor, including both positive and silencing allosteric modulators of the M4 muscarinic acetylcholine receptor.
[0046] As used herein, the phrase “mental disorder” refers to illnesses or disorders such as anxiety, personality disorders, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, attention deficit / hyperactivity disorder (ADHD), schizophrenia, substance use disorders, and other psychotic disorders.
[0047] As used herein, the phrase “neurological disease or disorder” refers to such diseases or disorders as Alzheimer’s disease, Rett syndrome, Huntington’s disease, vascular dementia, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
[0048] As used herein, the phrase “cognitive impairment” refers to such diseases or disorders as amnesia, dementia, amnestic disorder, dementia caused by Alzheimer’s disease, dementia caused by human immunodeficiency virus (HIV), dementia caused by Huntington’s disease, dementia caused by Parkinson’s disease, Lewy body dementia, vascular dementia, frontotemporal dementia, senile dementia, dementia associated with Down syndrome, and dementia associated with Tourette syndrome.Dementia associated with Tourette's syndrome, dementia associated with postmenopause, dementia in Creutzfeldt-Jakob disease, substance-induced persistent dementia, dementia in Pick's disease, dementia in Huntington's disease, traumatic brain injury, prions, HIV-related neurocognitive impairment, and mild cognitive impairment.
[0049] The term "patient" as used herein refers to an animal. Preferably, the term "patient" refers to a mammal. The term mammal includes mice, rats, dogs, rabbits, pigs, monkeys, horses, guinea pigs, and humans. More preferably, a patient is a human.
[0050] Embodiments
[0051] Without any limitation, the present invention covers all compounds described by compounds of formula (I), however, some preferred aspects and elements of the invention are discussed herein in the following embodiments.
[0052] In one embodiment, the present invention relates to a compound of formula (I), or an isotopic form or stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0053] Specification 5 / 50 pages 11 CN 122003415 A
[0054] wherein,
[0055] may each be a single bond or a double bond independently;
[0056] X1 is N or C, provided that R1 is absent when X1 is N;
[0057] X2, X3, X4, X5 and X6 are independently selected from N or C, provided that at least one of X2, X3, X4, X5 and X6 is C; and provided that R2, R3 or R4 is absent when X4, X5 or X6 is N;
[0058] R1, when present, is selected from hydrogen, halogen, cyano, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C1-C4 alkoxyalkyl;
[0059] R2, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0060] R3, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0061] R4, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0062] R5 is selected from hydrogen, halogen, -NH2, -NHCH3, C1-C4 alkyl, C1-C4 alkoxyalkyl, C3-C7 cycloalkyl, or C4-C10 heteroalkyl.Cycloalkyl;
[0063] R6 is independently selected from hydrogen or C1-C4 alkyl;
[0064] A is selected from 3- to 7-membered cycloalkyl or 4- to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, halogen, deuterium, cyano, -OC1-C4 alkyl and C1-C4 haloalkyl;
[0065] B is selected from 6- to 10-membered aryl or 5- to 10-membered heteroaryl, wherein the aryl and heteroaryl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, -NH2, NHCH3, C1-C4 alkyl, C1-C4 haloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl and C3-C7 cycloalkyl; and
[0066] n is an integer from 0 to 3.
[0067] In some embodiments, the compound of formula (I) is further defined by formula (Ia) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, wherein all variables shown are as defined in formula (I) above,
[0068] .
[0069] In some embodiments, the compound of formula (I) is further defined by formula (Ib) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, wherein all variables shown are as defined in formula (I) above,
[0070] . Instructions for Use, 6 / 50 pages, 12 CN 122003415 A
[0071] In another embodiment, the present invention relates to a method for treating or preventing diseases or disorders mediated by muscarinic M4 receptors, the method comprising administering to a patient a therapeutically effective amount of a compound having the structure of formula (I), or an isotopic form or stereoisomer thereof or a pharmaceutically acceptable salt thereof,
[0072]
[0073] wherein,
[0074] each may be a single bond or a double bond independently;
[0075] X1 is N or C, provided that R1 is absent when X1 is N;
[0076] X2, X3, X4, X5 and X6 are independently selected from N or C, provided that at least one of X2, X3, X4, X5 and X6 is C; and provided that R2, R3 or R4 is absent when X4, X5 or X6 is N;
[0077] R1, when present, is selected from hydrogen, halogen, cyano, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C1-C4 alkoxyalkyl;
[0078] R2, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0079] R3, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0080] R4, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH, or C1-C4 alkoxyalkyl;
[0081] R5 is selected from hydrogen, halogen, -NH2, -NHCH3, C1-C4 alkyl, C1-C4 alkoxyalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl;
[0082] R6 is independently selected from hydrogen or C1-C4 alkyl;
[0083] A is selected from 3- to 7-membered cycloalkyl or 4- to 10-membered heterocyclic alkyl, wherein the cycloalkyl and heterocyclic alkyl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, halogen, deuterium, cyano, -OC1-C4 alkyl, and C1-C4 haloalkyl;
[0084] B is selected from 6 to 10 aryl or 5 to 10 heteroaryl, wherein the aryl and heteroaryl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, -NH2, NHCH3, C1-C4 alkyl, C1-C4 haloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl and C3-C7 cycloalkyl; and
[0085] n is an integer from 0 to 3.
[0086] In another embodiment, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof: Specification 7 / 50 pages 13 CN 122003415 A
[0087]
[0088] wherein,
[0089] may each be a single bond or a double bond independently;
[0090] X1 is selected from C or N;
[0091] X2 is selected from C or N;
[0092] X3 is selected from C or N;
[0093] X4 is selected from C or N;
[0094] X5 is selected from C or N;
[0095] X6 is selected from C or N;
[0096] provided that at least one of X1, X2, X3, X4, X5 and X6 is C; provided that when X1, X2, X3, X4, X5 or X6 is N, then R1, R2, R3 or R4 is absent;
[0097] R1, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl;
[0098] R2, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl;
[0099] R3, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C4 cycloalkyl, or C4-C10 heterocyclic alkyl;
[0100] R4, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl;
[0101] R5 is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C10 heterocyclic alkyl; and
[0102] R6 is selected from hydrogen or C1-C4 alkyl.
[0103] In another embodiment, the present invention relates to a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein R1 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2, or CF3; wherein R2 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2, or CF3; wherein R3 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2, or CF3; wherein R4 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2, or CF3; wherein R5 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2, or CF3; and wherein R6 is selected from hydrogen, methyl, or ethyl.
[0104] In another embodiment, the ring is selected from:
[0105]
[0105]
[0106] 8 / 50 pages of specification 15 CN 122003415 A.
[0106] In another embodiment, the present invention relates to a compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, selected from:
[0107] 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0108] 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone;
[0109] 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0110] 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-acetone;
[0111] 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-4-yl-azacyclobutane-3-yl)-acetone;
[0112] 2-[1-(2-chloro-5-methoxy-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-acetone;
[0113] (2,5-Dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-methyl ketone;
[0114] (2,5-Dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-(1-pyridin-3-yl-pyrrolidine-3(R)-yl)-methyl ketone;
[0115] 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone;
[0116] 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-ethyl ketone;
[0117] 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone;
[0118] 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-(1-pyridin-4-yl-azacyclobutane-3-yl)-ethyl ketone;
[0119] 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-acetone;
[0120] 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(3-trifluoromethyl-phenyl)-azacyclobutane-3-yl]-acetone;
[0121] (4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-methyl ketone;
[0122] 1-(4-methyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0123] 1-(4-methyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0124] 1-(4-methyl-1,3-dihydro-2,7,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0125] 1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0126] 1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0127] 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-acetone;
[0128] 1-(4,5-dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0129] 1-(4,5-dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone;
[0130] 1-(4,5-dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0131] 2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(3,4,5-trimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-acetone;
[0132] 1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0133] 1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-2- (1-Pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0134] 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone;
[0135] 2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone;
[0136] 2-(1-pyridin-3-yl-azacyclobutane-3-yl)-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; Specification 11 / 50 pages 17 CN 122003415 A
[0137] 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone;
[0138] 1-(4,5-dimethyl-6,8-dihydro-1,3a) ,7-triaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0139] 1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone;
[0140] 1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0141] 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-acetone;
[0142] (4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-acetone;
[0143] 1-(5-methyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0144] 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone;
[0145] 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0146] 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2- [1-(2-Difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0147] 1-(2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0148] 1-(2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0149] 1-(2,5-dimethyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0150] 1-(2,5-dimethyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0151] 1-(4-methyl-1,3-dihydro-2,5,6,8a-tetraaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone;
[0152] 1-(4-methyl-1,3-dihydro-2,5,6,8a-tetraaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone;
[0153] 1-(1,5-dimethyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; or
[0154] 1-(1,5-dimethyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone.
[0155] Experimental Procedure
[0156] The following scheme describes a general method for preparing compounds of formula (I), wherein X1, X2, X3, X4, X5, X6, R1, R2, R3, R4, R5, R6, n, A and B are as defined above. Furthermore, G is a leaving group selected from OH or halogens. Specification 12 / 50 pages 18 CN 122003415 A
[0157] Scheme:
[0158]
[0159] Preparation of compound (I)
[0160] In the presence of a coupling agent selected from HATU, TBTU, pyBop, or triethylamine, in a solvent selected from DMF, THF, or DCM, compound 1 is reacted with compound 2 at room temperature for 4 to 16 hours. The resulting reaction mixture is extracted with a suitable organic solvent, washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum to obtain a residue.The residue is purified by column chromatography to obtain compound (I).
[0161] Preparation of pharmaceutically acceptable salts of compound (I)
[0162] Compound (I) can optionally be converted into its pharmaceutically acceptable salt by reaction with a suitable acid or base. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art. These salts are formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid) or organic acids (e.g., oxalic acid, succinic acid, maleic acid, acetic acid, citric acid, malic acid, tartaric acid, benzoic acid, p-toluenesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, methanesulfonic acid or naphthalenesulfonic acid).
[0163] Preparation of stereoisomers of compound (I)
[0164] Stereoisomers of compound (I) can be prepared by one or more conventional methods shown below:
[0165] a. One or more reagents can be used in their optically active form.
[0166] b. Optically pure catalysts or chiral ligands and metal catalysts can be used in the reduction process. The metal catalyst can be rhodium, ruthenium, indium, etc. The chiral ligand can preferably be a chiral phosphine.
[0167] c. The mixture of stereoisomers can be resolved by conventional methods (e.g., forming diastereomeric salts with chiral acids, chiral amines, chiral amino alcohols, or chiral amino acids). The resulting diastereomeric mixture can then be separated by methods such as fractional crystallization, chromatography, etc., followed by another step, i.e., separating the optically active product from the resolved material salt.
[0168] d. The mixture of stereoisomers can be resolved by conventional methods (e.g., microbial resolution, resolution of diastereomeric salts formed with chiral acids or chiral bases). The chiral acids that can be used can be tartaric acid, mandelic acid, lactic acid, camphor sulfonic acid, amino acids, etc. The chiral bases that can be used can be cinchona alkaloids, strychnine, or basic amino acids (e.g., lysine, arginine, etc.).
[0169] In another embodiment, suitable pharmaceutically acceptable salts include acetates, hydrochlorides, hydrobromides, oxalates, fumarates, tartrates, maleates, benzoates, methanesulfonates, and succinates.
[0170] In another embodiment of the invention, the compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt is used as a positive allosteric modulator (PAM) of the muscarinic M4 receptor.
[0171] In another embodiment of the invention, the compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt is used to prepare a medicament for treating or preventing diseases or disorders mediated by the muscarinic M4 receptor.
[0172] In another embodiment, the invention relates to a method for treating or preventing diseases or disorders mediated by the muscarinic M4 receptor in a patient, the method comprising administering a therapeutically effective amount of the compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt to a patient in need of such treatment.
[0173] In another embodiment, the present invention relates to a method of treating or preventing diseases or disorders mediated by muscarinic M4 receptors, said diseases or disorders being selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.
[0174] In another embodiment, the present invention relates to a compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt for treating diseases or disorders selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.
[0175] In another embodiment, the present invention relates to the use of a compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt for treating diseases or disorders selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.
[0176] In another embodiment, the present invention relates to the use of a compound of formula (I) or its isotopic form, stereoisomer, or pharmaceutically acceptable salt in the preparation of a medicament for treating diseases or disorders selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.
[0177] In some embodiments, the mental disorder is selected from anxiety, personality disorder, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, attention deficit / hyperactivity disorder (ADHD), schizophrenia, substance use disorder, and other psychotic disorders.
[0178] In some embodiments, other psychotic disorders include psychosis associated with Alzheimer's disease, psychosis associated with Parkinson's disease, psychotic depression, psychosis associated with stroke, psychosis associated with epilepsy, psychosis associated with multiple sclerosis, psychosis associated with traumatic brain injury, substance-induced persistent delirium, or any other illness with psychotic features.
[0179] In some embodiments, the neurological disease or disorder is selected from Alzheimer's disease, Rett syndrome, Huntington's disease, vascular dementia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
[0180] In some embodiments, cognitive impairment is selected from amnesia, dementia, amnesia disorder, dementia caused by Alzheimer's disease, dementia caused by HIV, dementia caused by Huntington's disease, dementia caused by Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia (FTD), senile dementia, dementia associated with Down syndrome, dementia associated with Tourette syndrome, dementia associated with postmenopausal syndrome, Kreutzfeldt-Jacob dementia, substance-induced persistent dementia, Pick's disease dementia, Huntington's disease dementia, traumatic brain injury, prions, HIV-related neurocognitive impairment, mild cognitive impairment, or any other disease with cognitive symptoms.
[0181] In some embodiments, the present invention relates to a method of treating or preventing a disease or disorder mediated by muscarinic M4 receptors, said disease or disorder being selected from schizophrenia.
[0182] In some embodiments, treatment of schizophrenia includes treating schizophrenic cognitive impairment, positive symptoms of schizophrenia, and / or negative symptoms of schizophrenia.
[0183] In some embodiments, schizophrenic cognitive impairment includes, but is not limited to, attention and alertness, concentration, executive function, processing speed, verbal learning, working memory, problem-solving, and / or social cognition.
[0184] In some embodiments, positive symptoms of schizophrenia include, but are not limited to, hallucinations, delusions, conceptual confusion, agitation, grandiosity, suspicion / persecution, and hostility.
[0185] In some embodiments, negative symptoms of schizophrenia include, but are not limited to, emotional blunting, emotional withdrawal, poor relationships, passive / apathetic social withdrawal, difficulty with abstract thinking, lack of spontaneity and conversational fluency, and stereotyped thinking.
[0186] In another embodiment, the invention comprises a pharmaceutical composition. Such pharmaceutical compositions comprise a compound of formula (I) of the present invention, as specified on pages 14 / 50 of CN 122003415, or an isotopic form or stereoisomer thereof or a pharmaceutically acceptable salt thereof, presented together with a pharmaceutically acceptable carrier. The carrier may be solid, liquid, or both, and may be formulated together with the compound into a unit dose composition, such as pills, tablets, coated tablets, capsules, powders, granules, pellets, patches, implants, films, liquids, semi-solids, gels, aerosols, emulsions, elixirs, etc.
[0187] The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition suitable for such a route, and at a dose effective for the intended treatment. For example, the active compound and composition may be administered orally, rectally, parenterally, or topically.
[0188] The dose of the active compound may vary depending on factors such as the patient's age and weight, the nature and severity of the disease to be treated, and other factors. Therefore, any reference to compounds of general formula (I), their stereoisomers, and the therapeutically effective amount of their medicinal salts refers to the factors mentioned above.
[0189] The following abbreviations are used in this document:
[0190] AcOH: Acetic acid
[0191] AMP: Adenosine monophosphate
[0192] BINAP: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
[0193] BOC: tert-butyloxycarbonyl
[0194] CDCl3: deuterated chloroform
[0195] Cs2CO3: cesium carbonate
[0196] DCM: dichloromethane
[0197] DIBAL-H: diisobutylaluminum hydride
[0198] DMA.DMA: N,N-dimethylacetamide dimethyl acetal
[0199] DMAP: 4-(dimethylamino)pyridine
[0200] DMF: N,N-dimethylformamide
[0201] DMSO: dimethyl sulfoxide
[0202] EC50: half-maximum effective concentration
[0203] g: gram
[0204] HATU: 2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethylurea
[0205] hexafluorophosphate
[0206] h: hour
[0207] hM4 PAM: human muscarinic M4 positive allosteric modifier
[0208] IPA: isopropanol
[0209] MeOH: methanol
[0210] mL: milliliter
[0211] mol: mole
[0212] Na2CO3: sodium carbonate
[0213] NaOtBu: sodium tert-butoxide
[0214] Na2SO4: sodium sulfate
[0215] ppm: parts per million
[0216] psi: pounds per square inch
[0217] Pd(dppf)Cl2: 1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride Instruction manual, pages 15 / 50, CN 122003415 A
[0218] Pd2dba3: Tris(dibenzylacetone)dipalladium
[0219] POCl3: Phosphoryl chloride
[0220] pyBop: (benzotriazole-1-yloxy)tripyrrolidinylphosphine hexafluorophosphate
[0221] RT: Room temperature
[0222] SM: Raw material
[0223] THF: Tetrahydrofuran
[0224] TBTU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate
[0225] T3P: Propylphosphonic anhydride
[0226] Examples
[0227] The compounds of the present invention were prepared according to the following experimental procedure using suitable materials and conditions. The following examples are provided by way of illustration only and do not limit the scope of the invention.
[0228] Preparation of intermediates:
[0229] Intermediate-1: 2,5-dimethyl-7,8-dihydro-6H-1,3,7,8b-tetraaza-asymmetric indah hydrochloride
[0230] Step-1: 6-amino-2-chloro-4-methyl-nicotinamide
[0231] A stirred mixture of methanol-ammonia (150 mL, 12% w / v solution) and 2,6-dichloro-4-methyl-nicotinamide (30 g, 0.160 mol) in methanol (60 mL) was heated in a sealed tube at 110°C to 120°C for 24 hours. The reaction mixture was cooled to room temperature and concentrated to obtain a residue, which was purified by column chromatography using 5% to 10% ethyl acetate in DCM to obtain the title compound. Yield: 5.3 g (second elution -20%); Mass (m / z): 167.9, 169.7 (M+H)+.
[0232] Step-2: N-(6-chloro-5-cyano-4-methyl-pyridin-2-yl)-N'-hydroxy-acetamidine
[0233] At room temperature, N,N-dimethylacetamide dimethyl acetal (12.4 mL, 0.074 mol) was added to a stirred solution of 6-amino-2-chloro-4-methyl-nicotinamide (5 g, 0.029 mol) in isopropanol (50 mL), and the reaction mixture was subsequently refluxed at 80°C to 90°C for 3 hours. The reaction mixture was cooled to 55°C to 60°C, and hydroxylamine hydrochloride (5.1 g, 0.074 mol) was added, and the mixture was stirred at the same temperature for 16 hours, during which solids precipitated. These solids were filtered and dried under vacuum to obtain the title compound. Yield: 4.1 g (68%); ¹H-NMR mass (m / z): 225.0, 226.9 (M+H)+.
[0234] Step-3: 5-chloro-2,7-dimethyl-[1,2,4]triazolo[1,5-a]pyridine-6-carboxynitrile
[0235] At room temperature, a T3P solution (13 mL, 0.020 mol, 50% in ethyl acetate) was added to a stirred solution of N-(6-chloro-5-cyano-4-methyl-pyridin-2-yl)-N'-hydroxy-acetamidine (3 g, 0.013 mol) in THF (30 mL), and the reaction mixture was refluxed for 24 hours. The reaction mixture was concentrated to obtain a residue, which was diluted with water (100 mL) and alkalized with a saturated Na₂CO₃ solution, during which solids precipitated. These solids were concentrated from DCM to obtain the title compound. Yield: 2.2 g (80%); 1H-NMR mass (m / z): 207.0, 209.0 (M+H)+.
[0236] Step-4: Methyl 6-cyano-2,7-dimethyl-[1,2,4]triazolo[1,5-a]pyridine-5-carboxylate
[0237] PD(dppf)Cl2•DCM (1.33 g, 0.0016 mol) followed by triethylamine (7.82 mL, 0.054 mol) was added to a stirred solution of 5-chloro-2,7-dimethyl-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylonitrile (2.8 g, 0.013 mol) in methanol (150 mL), and the contents were heated at 70°C for 5 hours in an autoclave under a carbon monoxide pressure of 50 psi. The reaction mixture was cooled to room temperature, filtered, and concentrated to obtain a residue, which was then subjected to column chromatography using DCM at 25°C.Purification was performed with ethyl acetate from 1% to 40% to obtain the title compound. Yield: 0.7 g (25%); Mass (m / z): 231.0 (M+H)+.
[0238] Step-5: 2,5-Dimethyl-6,7-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-8-one
[0239] Raney nickel (2.8 g) was added to a solution of methyl 6-cyano-2,7-dimethyl-[1,2,4]triazolo[1,5-a]pyridine-5-carboxylic acid (0.7 g, 0.003 mol) in methanol (50 mL), and the reaction mixture was stirred under H2 (gas) balloon pressure for 48 hours. The reaction mixture was then filtered and concentrated to obtain a residue, which was purified by column chromatography using 8% to 10% MeOH in DCM to obtain the title compound. Yield: 0.35 g (55%); Mass (m / z): 202.9 (M+H)+.
[0240] Step-6: 2,5-Dimethyl-8-oxo-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester
[0241] At room temperature, Boc anhydride (0.91 g, 0.004 mol) followed by DMAP (30 mg, 0.0002 mol) was added to a stirred solution of 2,5-dimethyl-6,7-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-8-one (0.34 g, 0.0016 mol) in DCM (10 mL) and kept overnight. The reaction mixture was concentrated under vacuum to obtain a residue, which was purified by column chromatography using 2% to 4% MeOH in DCM to obtain the title compound. Yield: 0.38 g (65%); Mass (m / z): 303.2 (M+H)+.
[0242] Step-7: 8-hydroxy-2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester
[0243] DIBAL-H (0.28 g, 0.0019 mol) was added to a stirred solution of 2,5-dimethyl-8-oxo-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester (0.2 g, 0.0006 mol) in THF (10 mL) at 0 °C to 10 °C. The reaction mixture was stirred for an additional 3 hours at room temperature. Sodium sulfate decahydrate (1 g) and ethyl acetate (25 mL) were added to the reaction mixture, and the mixture was stirred for 1 hour and then filtered through a hyflow filter. The filtrate was concentrated under vacuum to obtain the title compound, which was used as is in the next step without further purification. Yield: 0.2g; mass (m / z): 305.1 (M + H)+.
[0244] Step-8: 2,5-Dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester
[0245] Sodium cyanoborohydride (0.10 g, 0.0016 mol) was added to a stirred solution of 8-hydroxy-2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester (0.2 g, 0.0006 mol) in acetic acid (10 mL) at room temperature and stirred for 16 hours. The reaction mixture was concentrated under vacuum to obtain a residue, which was purified by column chromatography using 2% to 4% MeOH in DCM to obtain the title compound. Yield: 0.1 g (55%); Mass (m / z): 288.9 (M+H)+.
[0246] Step-9: 2,5-Dimethyl-7,8-dihydro-6H-1,3,7,8b-tetraaza-asymmetric indarsen hydrochloride
[0247] IPA.HCl (2 mL, 10 volumes, 12% w / v solution) was added to a stirred solution of 2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester (0.1 g, 0.0003 mol) in methanol (10 mL), and the reaction mixture was kept at 50°C to 55°C for 5 hours, and then the reaction mixture was concentrated under vacuum to obtain the title compound (intermediate-1). Yield: 0.6 g (77%); Mass (m / z): 188.8 (M+H)+.
[0248] Intermediate-2: 4,7-dimethyl-2,3-dihydro-1H-2,6,8a-triaza-asymmetric indahienazate hydrochloride
[0249] Step-1: 5-chloro-2,7-dimethyl-imidazo[1,2-a]pyridine-6-carboxynitrile
[0250] At room temperature, chloroacetone (41 g, 0.447 mol) was added to a stirred solution of 6-amino-2-chloro-4-methyl-nicotinamide (5 g, 0.0298 mol, Step-1 of intermediate-1) in water (50 mL). The reaction mixture was refluxed at 100°C to 110°C for 48 hours. After cooling to room temperature, the reaction mixture was concentrated under vacuum to obtain a residue, which was then diluted with water (10 mL). The mixture was alkalized with a saturated Na₂CO₃ solution to a pH of 9 to 10, during which solids precipitated. These solids were filtered and dried under vacuum to obtain the title compound. Yield: 0.5 g (8.1%); Mass (m / z): 205.9, 207.8 (M+H)⁺.
[0251] Following the procedures given in steps 4 through 9 of intermediate-1, and with some non-critical changes, 5-chloro-2,7-dimethyl-imidazo[1,2-a]pyridine-6-carboxynitrile was converted to intermediate-2. Mass (m / z): 188.0 (M+H)+.
[0252] Intermediate-3: 4-methyl-2,3-dihydro-1H-2,6,8a-triaza-asymmetric indahienazate hydrochloride
[0253] Step-1: 5-chloro-7-methyl-imidazo[1,2-a]pyridine-6-carboxynitrile
[0254] At room temperature, chloroacetaldehyde (1.16 g, 0.0149 mol, 50% aqueous solution) was added to a stirred solution of 6-amino-2-chloro-4-methyl-nicotinamide (0.5 g, 0.00298 mol, Step-1 of intermediate-1) in ethanol (10 mL). The reaction mixture was refluxed at 75°C to 85°C for 16 hours. After cooling to room temperature, the reaction mixture was concentrated under vacuum to obtain a residue, which was then diluted with water (10 mL) and alkalized with saturated Na2CO3 solution to a pH of 9 to 10, during which solids precipitated. These solids were filtered and dried under vacuum to obtain the title compound. Yield: 0.46 g (80%); Mass (m / z): 191.8, 193.5 (M+H)+.
[0255] 5-chloro-7-methyl-imidazo[1,2-a]pyridine-6-carboxynitrile was converted to intermediate-3 following the procedure given in steps-4 to-9 of intermediate-1, with some non-critical changes. Mass (m / z): 174.1 (M+H)+.
[0256] Intermediate-4: 4,5-Dimethyl-7,8-dihydro-6H-2,3a,7-triaza-asymmetric indahedron hydrochloride
[0257] Step-1: 4-Methanesulfonyloxymethyl-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester
[0258] At 0°C to 5°C, methanesulfonyl chloride (1.8 mL, 0.023 mol) was added to 4-hydroxymethyl-6,7-dimethyl-1,3,3a,4-tetrahydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester (2.2 g, 0.0079 mol, prepared according to the procedure disclosed in step-2 of the preparation of P6 on page 77 of WO2018234953) and Et3N (3.4 mL, 0.023 mol). The solution was stirred in DCM on page 18 / 50 of the instruction manual (CN 122003415 A) and kept for 4 hours. The reaction mixture was then poured into water, and the product was extracted using DCM (50 mL × 3). The organic extracts were combined and extracted with saline (50 mol).Washed (mL), dried over Na2SO4, filtered, and concentrated under vacuum to obtain the title compound, which was used as is in the next step without further purification. Yield: 3.3 g; mass (m / z): 357.0 (M+H)+.
[0259] Step-2: 4-Aminomethyl-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester
[0260] Methanol ammonia (30 mL, 12% w / v solution) was added to a stirred solution of 4-methanesulfonyloxymethyl-6,7-dimethyl-1,3,3a,4-tetrahydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester (3.3 g, 0.009 mol) in methanol (30 mL) at room temperature and maintained for 16 hours. The reaction mixture was concentrated under vacuum to obtain the title compound, which was used as is in the next step without further purification. Yield: 3.2 g; Mass (m / z): 277.8 (M+H)+.
[0261] Step-3: 4-Formylaminomethyl-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester
[0262] Ethyl formate (64 mL, 20 mol) was added to a stirred solution of 4-aminomethyl-6,7-dimethyl-1,3,3a,4-tetrahydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester (3.2 g, 0.011 mol) and Et3N (5 mL, 0.034 mol) in ethanol (10 mL) at room temperature. The reaction mixture was refluxed for 7 hours, cooled to room temperature, poured into water, and the product was extracted using DCM (50 mL × 3). The organic extracts were combined, washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated under vacuum to obtain the title compound, which was used as is in the next step without further purification. Yield: 2.0 g; mass (m / z): 306.2 (M+H)⁺.
[0263] Step-4: 4,5-Dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester
[0264] At 0°C to 5°C, POCl3 (1.58 mL, 0.016 mol) was added to a stirred solution of 4-formylmethyl-6,7-dimethyl-1,3,3a,4-tetrahydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester (2 g, 0.006 mol) and Et3N (6.0 mL, 0.041 mol) in DCM (25 mL), and then stirred at room temperature for 30 minutes. The reaction mixture was poured into water, alkalized to pH 9 to 10 with saturated Na2CO3 solution, and the product was extracted using DCM (50 mL × 3). The organic extracts were combined and extracted with brine (50 mL × 3).Washed (mL), dried over Na2SO4, filtered and concentrated under vacuum to obtain a residue, which was purified by column chromatography using 1.5% to 2.0% MeOH in DCM to obtain the title compound. Yield: 0.4 g (22%); Mass (m / z): 288.4 (M+H)+.
[0265] Step-5: 4,5-Dimethyl-7,8-dihydro-6H-2,3a,7-triaza-asymmetric indarsen hydrochloride
[0266] IPA.HCl (1 mL, 18% w / v solution) was added to a stirred solution of 4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester (0.13 g, 0.0004 mol) in methanol (10 mL), and the reaction mixture was kept at room temperature for 5 hours, and then the reaction mixture was concentrated under vacuum to obtain the title compound. Yield: Quantitative; Mass (m / z): 188.0 (M+H)+.
[0267] Intermediate-5: 4-methyl-2,3-dihydro-1H-2,7,8a-triaza-asymmetric indahedron hydrochloride
[0268] 4-methyl-2,3-dihydro-1H-2,7,8a-triaza-asymmetric indahedron hydrochloride was prepared from tert-butyl 2-hydroxymethyl-4-methyl-5,7-dihydro-pyrrolo[3,4-b]pyridine-6-carboxylic acid (prepared according to the procedure disclosed in steps 1 to 4 of WO2018002760, pages 82 and 83, p5, specification 19 / 50, 25 CN 122003415 A) according to the procedure described in steps 1 to 5 of intermediate-4 with some non-critical variations. Yield: 0.086 (70%); Mass (m / z): 174.1 (M+H)+.
[0269] Intermediate-6: 4,5-dimethyl-7,8-dihydro-6H-1,2,3a,7-tetraaza-asymmetric indarsen hydrochloride
[0270] Step-1: 4-chloro-6,7-dimethyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine hydrochloride
[0271] POCl3 (15 mL, 5 volumes relative to SM) was added to 6,7-dimethyl-4-oxo-1,3,4,5-tetrahydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester (3 g, 0.0113 mol, prepared according to the procedure disclosed in step-1 of the preparation of P1 on page 70 of WO2018234953) at 0 to 10 °C, and the reaction mixture was subsequently maintained at 90 to 100 °C for 16 hours. The reaction mixture was concentrated under vacuum to obtain the title compound. Yield: 2.0 g; Mass (m / z): 182.2, 183.3 (M+H)+.
[0272] Step 2: 4-Chloro-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester
[0273] At room temperature, Boc anhydride (4.97 g, 0.0228 mol) was added to a stirred solution of 4-chloro-6,7-dimethyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine hydrochloride (2.0 g, 0.0091 mol) and Et3N (4.61 g, 0.0456 mol) in DCM (40 mL) and maintained for 4 hours. The reaction mixture was poured into water, and the product was extracted using DCM (50 mL × 3). The organic extracts were combined, washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under vacuum to obtain a residue, which was purified by column chromatography using 1% to 2% MeOH in DCM to obtain the title compound. Yield: 1.1 g (42%); Mass (m / z): 282.4, 284.7 (M+H)+.
[0274] Step-3: 4-Hydroxy-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester
[0275] Hydrazine hydrate (5 mL, 5 volumes relative to SM) was added to a stirred solution of 4-chloro-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester (1 g, 0.0035 mol) in ethanol (10 mL), and the reaction mixture was refluxed for 48 hours. The reaction mixture was concentrated under vacuum to obtain a residue, which was purified by column chromatography using 1% to 5% MeOH in DCM to obtain the title compound. Yield: 150 mg (15%); Mass (m / z): 279.2 (M+H)+.
[0276] Step-4: 4,5-Dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester
[0277] A mixture of triethyl orthoformate (3 mL, 20 volumes relative to SM) and 4-hydrazino-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester (0.15 g, 0.00053 mol) was stirred in a sealed tube at 150°C to 160°C for 6 hours. The reaction mixture was cooled to room temperature and concentrated under vacuum to obtain a residue, which was purified by column chromatography using 1% to 5% MeOH in DCM to obtain the title compound. Yield: 0.11 g (72%); Mass (m / z): 288.7 (M+H)+.
[0278] Step-5: 4,5-Dimethyl-7,8-dihydro-6H-1,2,3a,7-tetraaza-asymmetric indah hydrochloride
[0279] IPA.HCl (0.25 mL, 0.00170.1 g (18% w / v solution) was added to a stirred solution of 4,5-dimethyl-6,8-dihydro-1,3a,7-tetraaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester (0.1 g, 0.0003 mol) in methanol (10 mL), and stirred at 50°C to 55°C for 5 hours. The reaction mixture was concentrated under vacuum to obtain the title compound. Yield: 60 mg (77%); Mass (m / z): 188.8 (M+H)+.
[0280] Intermediate-7: 3,4,5-trimethyl-7,8-dihydro-6H-1,2,3a,7-tetraaza-asymmetric indah hydrochloride
[0281] Intermediate-7 was obtained by following the procedure given in steps-1 to-5 of intermediate-6 with some non-critical changes, wherein in step-4, triethyl orthoacetate was used instead of triethyl orthoformate in the reaction. Mass (m / z): 203.0 (M+H)+.
[0282] Intermediate-8: 2,5,6-trimethyl-8,9-dihydro-7H-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridine hydrochloride:
[0283] Step-1: 4-[(N-hydroxy-acetylimino)-amino]-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester
[0284] 4-[(N-hydroxy-iminoacetyl)-amino]-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester is derived from 4-amino-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid tert-butyl ester (2.3 g, 0.00871, prepared according to the procedure disclosed in step 1 of the preparation of P3 on page 73 of WO2018234953) was prepared according to the procedure described in step 2 of intermediate-1 with some non-critical changes. Yield: 1.5 g (53%); mass (m / z): 320.1 (M+H)+.
[0285] Step-2: 2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridine-8-carboxylic acid tert-butyl ester
[0286] 2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridine-8-carboxylic acid tert-butyl ester was prepared by using the procedure described in step 3 of intermediate-1 with some non-critical changes. Yield: 0.5 g (45%); Mass (m / z): 303.2 (M+H)+.
[0287] Step-3: 2,5,6-trimethyl-8,9-dihydro-7H-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridine
[0288] 2,5,6-Trimethyl-8,9-dihydro-7H-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridine hydrochloride was prepared by using the procedure described in step-9 of intermediate-1 with some non-critical changes. Yield: 60 mg (77%); Mass (m / z): 203.0 (M+H)+.
[0289] Intermediate-9: 5,6-Dimethyl-8,9-dihydro-7H-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridine hydrochloride
[0290] Intermediate-9 was obtained by following the procedure given in steps-1 to-3 of intermediate-8 with some non-critical changes. In step-1 of intermediate-9, dimethylformamide dimethyl acetal is used instead of dimethylformamide dimethyl acetal in the reaction. (See page 21 / 50 of the specification, CN 122003415 A for details.) Yield: 60 mg (80%); Mass (m / z): 188.9 (M+H)+.
[0291] Intermediate-10: 4,5-dimethyl-7,8-dihydro-6H-1,3a,7-triaza-asymmetric indahedron hydrochloride
[0292] Step-1: ethyl 4-chloro-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylate
[0293] Ethyl chloroformate (0.8 mL, 0.0082 mol) was added to a stirred solution of 4-chloro-6,7-dimethyl-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine hydrochloride (1.5 g, 0.0068 mol) and triethylamine (2.9 mL, 0.02 mol) in dichloromethane (50 mL) at 0 to 10 °C, and then stirred at room temperature for 3 hours. The reaction mixture was then poured into water (50 mL) and the product was extracted with dichloromethane (50 mL × 2). The organic extracts were combined, washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under vacuum to obtain a residue, which was purified by column chromatography using 25% to 30% ethyl acetate in hexane to obtain the title compound. Yield: 1.07 g (61%); Mass (m / z): 255.0, 257.0 (M+H)+.
[0294] Step-2: 4-(2,2-dimethoxy-ethylamino)-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid ethyl ester
[0295] Pd2dba3 (0.19 g, 0.00021 mol), BINAP (0.26 g, 0.00042 mol) and NaotBu (0.81 g, 0.0084 mol) were added.4-chloro-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylic acid ethyl ester (1.07 g, 0.0042 mol) and aminoacetaldehyde dimethyl acetal (0.53 g, 0.0050 mol) in toluene were added sequentially to a stirred solution, and the reaction mixture was refluxed under N2 atmosphere for 6 hours. The reaction mixture was then poured into water, and the product was extracted using DCM (50 mL × 3). The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum to obtain a residue, which was purified by column chromatography using 1% to 2% MeOH in DCM to obtain the title compound. Yield: 0.85 g (63%); Mass (m / z): 324.1 (M+H)+.
[0296] Step-3: Ethyl 4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-carboxylate
[0297] A mixture of ethyl 4-(2,2-dimethoxy-ethylamino)-6,7-dimethyl-1,3-dihydro-pyrrolo[3,4-c]pyridine-2-carboxylate (0.85 g, 0.0026 mol) and trifluoroacetic acid (25 mL) was refluxed for 48 hours. The reaction mixture was then concentrated to obtain a crude product. The crude product was diluted with cold water (100 mL), alkalized with dilute NaOH solution (pH approximately 12), and extracted with DCM (50 mL × 3). The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum to obtain the title compound. Yield: 0.38 g (55%); 28 CN 122003415 A, Page 22 / 50, Instructions for Use. Mass (m / z): 260.0 (M+H)+.
[0298] Step-4: 4,5-Dimethyl-7,8-dihydro-6H-1,3a,7-triaza-asymmetric indarsen-7-carboxylic acid ethyl ester (0.38 g, 0.0014 mol) was refluxed for about 24 hours. The reaction mixture was then concentrated to obtain the title compound. Yield: 0.32 g (100%); Mass (m / z): 188.0 (M+H)+.
[0300] Intermediate-11: 5-azacyclobutane-1-yl-7,8-dihydro-6H-2,3,4,7,8b-pentaaza-asymmetric indahedron hydrochloride
[0301] Step-1: 4-azacyclobutane-1-yl-2-chloro-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester
[0302] Under a nitrogen atmosphere, 2.94 g (0.031 mol) of aziridine hydrochloride was added to a stirred solution of 2,4-dichloro-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester (7.6 g (0.026 mol)) in 250 mL of THF, followed by the addition of diisopropylethylamine (13.89 mL (0.078 mol)). The reaction mixture was then stirred at room temperature for 16 hours. The reaction mixture was concentrated to obtain a residue, which was purified by column chromatography using 50% to 60% ethyl acetate in hexane to obtain the title compound. Yield: 6.2 g (76%). Mass (m / z): 310.9, 312.8 (M+H)+.
[0303] Step-2: 4-azacyclobutane-1-yl-2-hydrazino-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester
[0304] Hydrazine hydrate (0.02 mL, 0.0053 mol) was added to a stirred solution of 4-azacyclobutane-1-yl-2-chloro-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester (1.1 g, 0.387 mol) in 1,4-dioxane (10 mL), and the reaction mixture was refluxed for 7 hours, during which solids precipitated. These solids were filtered and dried under vacuum to obtain the title compound. Yield: 0.3 g (88%); Mass (m / z): 307.36 (M+H)+.
[0305] Step-3: 5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester
[0306] Triethyl orthoformate (11.8 mL, 0.072 mol) was added to a stirred solution of 4-azacyclobutane-1-yl-2-hydrazyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester (1.1 g, 0.036 mol) in THF (20 mL). The mixture was heated in a sealed tube at 170 °C for 6 hours, followed by heating at 100 °C for 16 hours. The reaction mixture was cooled to room temperature and concentrated to obtain a residue, which was purified by column chromatography using 4% to 6% MeOH in DCM to obtain the title compound. Yield: 0.88 g (77%); Mass (m / z): 317.3, (M+H)+.
[0307] Step-4: 5-azacyclobutane-1-yl-7,8-dihydro-6H-2,3,4,7,8b-pentaaza-asymmetric indah hydrochloride
[0308] IPA.HCl (4.4 mL, 10 volumes relative to SM, 12% w / v solution) was added to 5-azacyclobutane-1-yl-7,8-dihydro-6H-2,3,4,7,8b-pentaaza-asymmetric indah hydrochloride.A stirred solution of 0.88 g (0.002 mol) of 6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester was prepared in MeOH (10 mL), and the reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was then concentrated under vacuum to obtain the title compound. Yield: 0.52 g (74%). Mass (m / z): 217.0 (M+H)+.
[0309] Intermediate-12: 5-methyl-7,8-dihydro-6H-2,3,4,7,8b-pentaza-asymmetric indah hydrochloride
[0310] Step-1: 2-chloro-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester
[0311] Methyl zinc chloride (17.2 mL, 0.034 mol, 2 M solution in THF) was added to a stirred solution of 2,4-dichloro-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester (10 g, 0.034 mol) in THF (100 mL), followed by the addition of PD(dppf)Cl2•CH2Cl2 (0.84 g, 0.001 mol) under N2 atmosphere, and the reaction mixture was then refluxed for 4 hours. The reaction mixture was cooled to room temperature and concentrated to obtain a residue, which was purified by column chromatography using 20% to 25% ethyl acetate in hexane to obtain the title compound. Yield: 3.5 g (37%). Mass (m / z): 270.0 (M+H)+.
[0312] Step-2: 2-Hydroxy-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester
[0313] Hydrazine hydrate (0.15 mL, 3.011 mol) was added to a stirred solution of 2-chloro-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester (0.27 g, 0.013 mol) in 1,4-dioxane (10 mL), and the reaction mixture was refluxed for 7 hours, during which solids precipitated. These solids were filtered and dried under vacuum to obtain the title compound. Yield: 0.3 g (88%); Mass (m / z): 265.7, (M+H)+.
[0314] Step-3: 5-methyl-6,8-dihydro-2,3,4,7,8b-pentazon-asymmetric indane-7-carboxylic acid tert-butyl ester
[0315] Triethyl orthoformate (1.8 mL, 0.011 mol) was added to a stirred solution of 2-hydrazino-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidine-6-carboxylic acid tert-butyl ester (0.15 g, 0.0005 mol) in THF (20 mL) in a sealed tube.They were heated at 170°C for 6 hours, and then at 100°C for 16 hours. The reaction mixture was cooled to room temperature and concentrated to obtain a residue, which was purified by column chromatography using 4% to 6% MeOH in DCM to obtain compound 30 CN 122003415 A, title specification, page 24 / 50. Yield: 0.06 g (38%); Mass (m / z): 275.9 (M+H)+.
[0316] Step-4: 5-Methyl-7,8-dihydro-6H-2,3,4,7,8b-pentaza-asymmetric indarsen hydrochloride
[0317] IPA·HCl (3.5 mL, 10 volumes relative to SM, 12% w / v solution) was added to a stirred solution of 5-methyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-carboxylic acid tert-butyl ester (0.06 g, 0.218 mol) in MeOH (50 mL), and the reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was then concentrated under vacuum to obtain the title compound. Yield: 0.032 g (69%). Mass (m / z): 175.9(M+H)+.
[0318] Intermediate-13: 1-(2-amino-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone
[0319] Step-1: 2-chloro-4-methyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin hydrochloride
[0320] IPA·HCl (35 mL, 10 volumes relative to SM, 12% w / v solution) was added to a stirred solution of tert-butyl 2-chloro-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-carboxylic acid (3.5 g, 0.013 mol) in MeOH (50 mL), and the reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was then concentrated under vacuum to obtain the title compound. Yield: 2.5 gm. Mass (m / z): 169.8(M+H)+.
[0321] Step-2: 1-(2-chloro-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone
[0322] HATU (4.38 g, 0.01 mol) was added to a stirred solution of [1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetic acid (2.5 g, 0.009 mol) in DMF (20 mL), followed by the addition of 2-chloro-4-methyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin hydrochloride (2.37 g, 0.01 mol).0.038 mol) and diisopropylethylamine (6.79 mL, 0.038 mol) were added, and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was then poured into cold water, and the product was extracted using DCM (100 mL × 3). The organic extracts were combined, washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum to obtain a residue, which was purified by column chromatography using 1% to 2% MeOH in DCM to obtain the title compound. Yield: 3.3 g; Mass (m / z): 412.0 (M+H)+.
[0323] Step-3: 1-[2-(4-methoxy-benzylamino)-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl]-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone
[0324] Potassium fluoride (1.0 g, 0.020 mol) was added to a stirred mixture of 1-(2-chloro-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone (2.8 g, 0.006 mol) and 4-methoxybenzylamine (2.7 g, 0.020 mol) in water (120 mL), and the reaction mixture was refluxed to the instruction manual 25 / 50. Page 31 CN 122003415 A Overnight. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (50 mL × 3). The organic extracts were combined, washed with brine (50 mL), dried over Na2SO4, and concentrated under vacuum to obtain a residue, which was purified by column chromatography using 2% to 3% MeOH in DCM to obtain the title compound. Yield: 2.6 g; Mass (m / z): 513.3 (M+H)+.
[0325] Step-4: 1-(2-amino-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone
[0326] A stirred mixture of trifluoroacetic acid (50 mL, 20 volumes) and 1-[2-(4-methoxy-benzylamino)-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl]-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone (2.6 g, 0.005 mol) was refluxed overnight, and the reaction mixture was subsequently concentrated to obtain the residue. The resulting substance was diluted with cold water (100 mL), alkalized with dilute NaOH solution, and the product was extracted with ethyl acetate (100 mL × 3). Combine the organic extracts and rinse with saline (100).The sample was washed (mL), dried over Na2SO4, and concentrated under vacuum to obtain a residue. This residue was purified by column chromatography in DCM with 3% to 5% MeOH to obtain the title compound. Yield: 1.28 g; Mass (m / z): 393.0 (M+H)+.
[0327] Intermediate-14: 1-(2-hydrazyl-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone
[0328] Hydrazine hydrate (0.02 mL, 0.00036 mol) was added to a stirred solution of 1-(2-chloro-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone (0.05 g, 0.00012 mol) in 1,4-dioxane (5 mL), and the reaction mixture was refluxed at 100°C to 110°C for 16 hours. The reaction mixture was concentrated to obtain a crude compound, which was then ground with hexane (3 mL × 2) to obtain the title compound. Yield: 0.035 g (71%); mass (m / z): 408.2, (M+H)+.
[0329] Intermediate-15: 2-Methyl-7,8-dihydro-6H-1,4,7,8b-tetraaza-asymmetric indarin
[0330] Step-1: 5-hydroxy-2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarin-7-carboxylic acid ethyl ester
[0331] 5-methyl-2H-pyrazole-3-ylamine (1.69 g, 0.017 mol) was added to a stirred solution of 4-oxo-pyrrolidine-1,3-dicarboxylic acid diethyl ester (4.0 g, 0.017 mol) in acetic acid (17.5 mL), and the reaction mixture was heated to 120 °C for 3 hours. The reaction mixture was cooled to room temperature and diluted with ethanol (35 mL) and diethyl ether (35 mL) with stirring for 30 minutes, during which solids precipitated. These solids were filtered through a Buchner funnel and dried under high vacuum to obtain the title compound. Yield: 3.01 g (65%); Instructions 26 / 50 pages 32 CN 122003415 A Mass (m / z): 263.2 (M+H)+.
[0332] Step-2: Ethyl 5-chloro-2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-carboxylate
[0333] At room temperature, ethyl 5-hydroxy-2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-carboxylate (1.0 g, 0.0038 mol) was reacted with acetonitrile (0.2 M, 19.0 mol) in acetonitrile (0.2 M, 19.0 mol).POCl3 (0.6 mol, 6.4 mL) was added to a stirred solution. The reaction mixture was heated under reflux for 6 hours and then cooled to room temperature. Volatiles were removed under reduced pressure. The reactants were diluted with ethyl acetate and washed with water followed by a salt solution. The organic layer was dried over anhydrous Na2SO4 and volatiles were removed under reduced pressure to obtain the title compound. Yield: 0.51 g (54%); Mass (m / z): 281.2, 283.0 (M+H)+.
[0334] Step-3: Ethyl 2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-carboxylate
[0335] At room temperature, pd / c (500.0 mg) was added to a stirred solution of 5-chloro-2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-carboxylate (1.0 g, 0.0034 mol) in methanol (0.25 M, 14.3 mL), and the mixture was stirred for 12 hours under H2 balloon. The mixture was filtered through diatomaceous earth, and volatiles were removed under reduced pressure to obtain the title compound. Yield: 0.8 g (91.9%); Mass (m / z): 247.2 (M+H)+.
[0336] Step-4: 7,8-Dihydro-2-methyl-6H-pyrazolo[1,5-a]pyrrolo[3,4-e]pyrimidine
[0337] At room temperature, potassium hydroxide (9.10 g, 0.162 mol) was added to a stirred solution of ethyl 2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-carboxylic acid (1.0 g, 0.0036 mol) in ethanol:water (1:1, 40 volumes). The reaction mixture was heated under reflux for 12 hours and then cooled to room temperature. Volatiles were removed under reduced pressure. The reaction mixture was extracted with ethyl acetate followed by a salt solution. The organic layer was dried over anhydrous Na2SO4 and volatiles were removed under reduced pressure to obtain the title compound. Yield: 0.41 g (58.0%); Mass (m / z): 175.3 (M+H)+.
[0338] Intermediate-16: 2,5-Dimethyl-7,8-dihydro-6H-1,4,7,8b-tetraaza-asymmetric inducible
[0339] Methylboronic acid (0.096 g, 0.001 mol), Pd(dppf)Cl2·DCM (0.087 g, 0.0001 mol) and sodium carbonate (0.45 g, 0.004 mol) were sequentially added to 5-chloro-2-methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric inducible-7-carboxylic acid ethyl ester (0.3 g, 0.001 mol, product of step-2 of intermediate-15) in 1,4-dioxane:H2O (5:1) Stirring solution. Heat the reaction mixture at 110°C for 7 hours. Pour the reaction mixture into water and extract the product using ethyl acetic acid (100 mL × 3). Combine the organic extracts, wash with brine (50 mL), dry over Na2SO4 and concentrate under vacuum to give ethyl 2,5-dimethyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-carboxylic acid. Convert the ester to intermediate 16 according to step 4 of the intermediate-15 procedure. Yield: 0.15 g (53.0%), mass (m / z): 189.2 (M+H)+.
[0340] Intermediate-17: [1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetic acid
[0341] Step-1: Azacyclobutane-3-yl-ethyl acetate hydrochloride
[0342] IPA.HCl (100 mL, 5 volumes, 12% w / v solution) was added to a stirred solution of ethoxycarbonylmethyl-azacyclobutane-1-carboxylic acid tert-butyl ester (20 g, 0.0823 mol; prepared according to the experimental procedure in ACS Medicinal Chemistry Letters (2021), 12(10), 1585-1588) at room temperature and kept overnight. The reaction mixture was then concentrated under vacuum to obtain the title compound, which was used as is in the next step without further purification. Yield: 11.5 g (78%); mass (m / z): 141.8 (M+H)+.
[0343] Step-2: [1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl acetate
[0344] Cesium fluoride (38.1 g, 0.250 mol) and triethylamine (47 mL, 0.334 mol) were sequentially added to a stirred solution of azacyclobutane-3-yl-ethyl acetate hydrochloride (15 g, 0.083 mol) and 4-bromo-2-trifluoromethyl-pyridine (19 g, 0.083 mol) in DMSO (60 mL), and the reaction mixture was kept at 110 °C for 4 hours. The reaction mixture was then poured into water, and the product was extracted with ethyl acetate (100 mL × 3). The organic extracts were combined, washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under vacuum to obtain a residue. This residue was purified by column chromatography using 15% to 25% ethyl acetate in hexane to obtain the title compound. Yield: 20 g (83%): Mass (m / z): 289.1 (M+H)+.
[0345] Step 3: [1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetic acid
[0346] Lithium hydroxide monohydrate (8.96 g, 0.109 mol) was added to a stirred solution of [1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl acetate (20 g, 0.071 mol) in THF (100 mL) and water (50 mL), and the reaction mixture was refluxed at 55°C to 60°C for 6 hours. The reaction mixture was then concentrated to obtain a crude product, which was diluted with cold water (100 mL), washed with diethyl ether (50 mL × 3), and the aqueous layer was separated. The aqueous layer was acidified with acetic acid (pH approximately 4), during which solids precipitated. These solids were filtered and concentrated from DCM (100 mL) under vacuum to obtain the title compound. Yield: 10.5 g (56%): Mass (m / z): 261.0 (M+H)+.
[0347] Intermediate-18: [1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetic acid
[0348] Step-1: [1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-ethyl acetate
[0349] Pd2dba3 (0.72 g, 0.0007 mol), BINAP (0.82 g, 0.001 mol), followed by Cs2CO3 (25.8 g, 0.079 mol) were sequentially added to azacyclobutane-3-yl-ethyl acetate hydrochloride (6.0 g, 0.0265 mol, intermediate-step-1 of step-1 of intermediate-17) and 5-bromo-2-trifluoromethyl-pyridine (5.7 g, 0.036 mol). The reaction mixture was stirred in toluene (60 mL) and refluxed under N2 atmosphere for 16 hours. The reaction mixture was then poured into water and the product was extracted using DCM (50 mL × 3). The organic extracts were combined, washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under vacuum to obtain the residue, which was purified by column chromatography using 15% to 25% ethyl acetate in hexane to obtain the title compound. Yield: 2.9 g (20%); Mass (m / z): 289.1 (M+H)+.
[0350] Step-2: [1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetic acid
[0351] [1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetic acid (intermediate-18) is produced from [1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-ethyl acetate (compound of step-1) according to the process described in step-3 of intermediate-17.The preparation was carried out with some non-critical changes. Yield: 1.5 g (55%); Mass (m / z): 261.0 (M+H)+.
[0352] Intermediate-19: (1-pyridin-3-yl-azacyclobutane-3-yl)-acetic acid
[0353] (1-pyridin-3-yl-azacyclobutane-3-yl)-acetic acid was prepared according to the procedure described in step-3 of intermediate-17 with some non-critical changes to obtain a crude compound. The resulting crude compound was ground with a hot solution of ethyl acetate:n-hexane (7:3, 10 volumes), and the resulting solid was filtered and dried under vacuum. Yield: 0.62 g (31%); Mass (m / z): 193.1 (M+H)+.
[0354] Intermediate-20: [1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetic acid
[0355] [1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetic acid was prepared according to the procedure described in step 1 of Example 12 on page 110 of WO2018 / 002760, with some non-critical variations. Yield: quantitative; Mass (m / z): 243.0 (M+H)+.
[0356] Intermediate-21: [1-(2-chloro-5-methoxy-pyridin-4-yl)-azacyclobutane-3-yl]-acetic acid
[0357] [1-(2-chloro-5-methoxy-pyridin-4-yl)-azacyclobutane-3-yl]-acetic acid was prepared according to the procedure described on pages 29 / 50 of the synthesis specification of intermediate-17, CN 122003415 A, with some non-critical variations. Mass (m / z): 256.4, 258.8 (M+H)+.
[0358] Intermediate-22: 2-(1-(pyridin-4-yl)azacyclobutane-3-yl)acetic acid
[0359] 2-(1-(pyridin-4-yl)azacyclobutane-3-yl)acetic acid was prepared according to the procedure given in reference J. Med. Chem. 2024, 67, 13, 10831-10847 (supporting information). Mass (m / z): 193.10.
[0360] Intermediate-23: 1-(3-trifluoromethyl-phenyl)-azacyclobutane-3-yl)-lithium acetate
[0361] [1-(3-trifluoromethyl-phenyl)-azacyclobutane-3-yl]-lithium acetate was prepared according to the procedure given in reference WO2024130066, page 86, for intermediate 24, with some non-critical variations. Mass (m / z): 260.1.
[0362] Intermediate-24: 1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-carboxylic acid
[0363] Step-1: Ethyl 1-(2-trifluoromethyl-pyridin-4-yl)-3(R)-pyrrolidinecarboxylate
[0364] Ethyl 1-(2-trifluoromethyl-pyridin-4-yl)-3(R)-pyrrolidinecarboxylate was obtained according to the procedure given in Step-2 of Intermediate-17 with some non-critical variations. Yield: quantitative; mass (m / z): 274.6 (M+H)+.
[0365] Step-2: 1-(2-trifluoromethyl-pyridin-4-yl)-3(R)-pyrrolidinecarboxylate
[0366] 1-(2-trifluoromethyl-pyridin-4-yl)-3(R)-pyrrolidinecarboxylate was obtained according to the procedure given in Step-3 of Intermediate-17 with some non-critical variations. Yield: 7.5 g (52%); mass (m / z): 260.9 (M+H)+.
[0367] Intermediate-25: 1-pyridin-3-yl-pyrrolidine-3(R)-carboxylic acid
[0368] Step-1: Ethyl 1-pyridin-3-yl-pyrrolidine-3(R)-carboxylic acid
[0369] Ethyl 1-pyridin-3-yl-pyrrolidine-3(R)-carboxylic acid was obtained according to the procedure given in Step-1 of Intermediate-18 with some non-critical variations. Yield: quantitative; mass (m / z): 221.3 (M+H)+.
[0370] Step-2: 1-pyridin-3-yl-pyrrolidine-3(R)-carboxylic acid
[0371] 1-pyridin-3-yl-pyrrolidine-3(R)-carboxylic acid was obtained according to the procedure given in Step-3 of Intermediate-17 with some non-critical variations. Yield: 49%; mass (m / z): 193.4 (M+H)+.
[0372] Example 1: 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2- Specification 30 / 50 pages 36 CN 122003415 A [1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone
[0373]
[0374] HATU (0.061 g, 0.00016 mol) was added to a stirred solution of [1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetic acid (0.038 g, 0.00014 mol, intermediate-17) in DMF (3 mL), followed by the addition of 2,5- Dimethyl-7,8-dihydro-6H-1,3,7,8b-tetraaza-asymmetric indarin hydrochloride (0.030 g, 0.00013 mol, intermediate-1) and diisopropylethylamine (0.094 mL, 0.00053 mol) were reacted and stirred at room temperature for 12 hours. The reaction mixture was poured into cold water (50 mL) and the product was extracted using DCM (15 mL × 3). The organic extracts were combined and extracted with brine (15 mL × 3).Washed (mL), dried over Na2SO4, filtered and concentrated under vacuum to obtain a residue, which was purified by column chromatography using 2% to 4% MeOH in DCM to obtain the title compound. Yield: 0.030 g (52%); Mass (m / z): 431.0 (M+H)+.
[0375] Examples 2 to 44 below were prepared according to the preparation experimental procedure described in Example 1, using suitable intermediates (synthesized or commercially available above) and with some non-critical variations. Instruction Manual Pages 31 / 50, 37 CN 122003415 A; Instruction Manual Pages 32 / 50, 38 CN 122003415 A; Instruction Manual Pages 33 / 50, 39 CN 122003415 A; Instruction Manual Pages 34 / 50, 40 CN 122003415 A; Instruction Manual Pages 35 / 50, 41 CN 122003415 A; Instruction Manual Pages 36 / 50, 42 CN 122003415 A; Instruction Manual Pages 37 / 50, 43 CN 122003415 A; Instruction Manual Pages 38 / 50, 44 CN 122003415 A; Instruction Manual Pages 39 / 50, 45 CN 122003415 A; Instruction Manual Pages 40 / 50, 46 CN 122003415 A; Instruction Manual Pages 41 / 50, 47 CN 122003415 A Instruction manual 42 / 50 pages 48 CN 122003415 A Instruction manual 43 / 50 pages 49 CN 122003415 A Instruction manual 44 / 50 pages 50 CN 122003415 A
[0376] Example 45: 1-(4-methyl-1,3-dihydro-2,5,6,8a-tetraaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone
[0377]
[0378] Chloroacetaldehyde (9.3 mL, 0.001 mol, 50% w / v solution) was added to 1-(2-amino-4-methyl-5-yl) 7-Dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone (0.6 g, 0.001 mol, intermediate-13) was stirred in water (50 mL), and the reaction mixture was refluxed overnight. The reaction mixture was cooled to room temperature, alkalized with saturated Na2CO3 solution, and the product was extracted with ethyl acetate (100 mL × 3). The organic extracts were combined, washed with brine (100 mL), dried over Na2SO4, and concentrated under vacuum to obtain the residue.The residue was purified by column chromatography using 3% to 5% MeOH in DCM to obtain the title compound. Yield: 0.21 g; Mass (m / z): 417.0 (M+H)+.
[0379] Example 46: 1-(4-methyl-1,3-dihydro-2,5,6,8a-tetraaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone
[0380]
[0381] Example 46 was prepared using suitable intermediates and with some non-critical variations, following the procedure described in Example 45. Mass (m / z): 349.40 (M+H)+.
[0382] Example 47: 1-(1,5-dimethyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone
[0383]
[0384] In a sealed tube, triethyl orthoacetate (2 mL) was added to a stirred solution of 1-(2-hydrazyl-4-methyl-5,7-dihydro-pyrrolo[3,4-d]pyrimidin-6-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone (0.035 g, 0.085 mmol, intermediate-14) in THF (10 mL), and the reaction mixture was heated at 170°C for 6 hours and then at 100°C for 16 hours. The reaction mixture was cooled to room temperature and concentrated to obtain a residue, which was purified by column chromatography using 8% to 10% MeOH in DCM to obtain the title compound. Yield: 0.0126 g (32%); Mass (m / z): 432.2, (M+H)+.
[0385] Example 48: 1-(1,5-dimethyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-acetone
[0386]
[0387] Example 48 was prepared using suitable intermediates and with some non-critical variations, following the procedure described in Example 47. Mass (m / z): 364.42 (M+H)+.
[0388] Example 49: Determination of the allosteric potency EC50 value of the muscarinic M4 receptor
[0389] The ability of these compounds to activate the muscarinic M4 receptor was tested. The experimental procedures and results are provided below. Specification 46 / 50 pages 52 CN 122003415 A
[0390] Experimental procedures
[0391] A. CRE-Luc reporter assay—The modified compound stably expressing recombinant human muscarinic M4 receptor and pCRE-Luc were used to determine the target compound.The CHO-K1 cell line (Chinese hamster ovary (CHO) K1 (ATCC CCL-61) purchased from ATCC) of the reporter system was used for cell-based assays. This assay provides a non-radioactive method for determining the binding of compounds to GPCRs. In this particular assay, intracellular cyclic AMP levels regulated by receptor activation or inhibition were measured. The recombinant cells possessed a luciferase reporter gene under the control of cyclic AMP response elements.
[0392] The above cells were grown in Hams F12 medium containing 10% fetal bovine serum (FBS, purchased from Thermo Fisher Scientific) in 96-well clear white plates. Cells were serum starved overnight before the addition of the compound or standard agonist. The test compound in escalating concentrations in Opti-MEM medium was added to the cells along with acetylcholine and trichodin (1 μM) at EC20.
[0393] The cells were further cultured at 37°C in a CO2 incubator for 4 hours. After removing the culture medium, cells were lysed using lysis buffer, assay reagents were added, and luciferase activity was measured in a photometer. The luciferase activity stimulated by a reference agonist (10 μM) in the presence of trichodin (1 μM) was set as 100%, while the basal luciferase activity, i.e., trichodin only (1 μM) without the reference agonist, was set as 0%. After correcting for the basal luciferase activity, the reference stimulation value was used to calculate the remaining luminescence values obtained at different concentrations of the compound. Compound activity (%) was plotted against compound concentration, and the dose-response curves were analyzed using a 4-parameter logistic fitting model in GraphPad Prism software. The EC50 value of the compound was defined as the concentration required to stimulate luciferase activity to 50% in the presence of EC20 acetylcholine, and the results are provided as EC50 in Table 1A.
[0394] Table 1A: Allosteric Power EC50 Values of Muscarinic M4 Receptor
[0395]
[0396] B. Glosensor cAMP Assay—HEK293 cell lines (human embryonic kidney cells (HEK-293) (ATCC CRL-1573) purchased from ATCC) modified to transiently express recombinant human muscarinic M4 receptor and pGloSensor-22F cAMP were used for the Glosensor cAMP assay. This assay provides a non-radioactive method for determining the binding of compounds to GPCRs using a genetically encoded biosensor variant with a cAMP-binding domain fused to a mutant form of firefly (Photinus pyralis) luciferase. Upon binding to cAMP, a conformational change occurs, resulting in a large light output.Increased amplitude. After preequilibration with substrate, GPCR function can be measured using a live-cell, non-lytic assay with cells that transiently or stably express biosensor variants. This assay allows for easy kinetic measurements of cAMP accumulation or turnover in live cells.
[0397] The cells were grown overnight in a 96-well clear white plate in Dulbecco modified Eagle medium containing glutamine and 10% fetal bovine serum (FBS, Thermo Fisher Scientific) at 37°C in a CO2 incubator. Cells were preequilibrated with substrate in a CO2-independent medium containing 10% FBS for 2 hours at room temperature before adding the compound or standard agonist. The test compound was added to the cells in increasing concentrations in a CO2-independent medium containing 10% FBS along with acetylcholine and isoproterenol (0.1 μM) from EC20.
[0398] Incubation was continued at room temperature for 12 minutes. After incubation, luciferase activity was measured in a photometer. The luciferase activity stimulated by a reference agonist (10 μM) in the presence of isoproterenol was set as 100%, while the basal luciferase activity, i.e., isoproterenol alone without a reference agonist, was set as 0%. After correcting for the basal luciferase activity, the reference stimulation value was used to calculate the remaining luminescence values obtained for the compound at various doses. Compound activity (%) was plotted against compound concentration, and the dose-response curve was analyzed using a 4-parameter logistic fitting model in GraphPad Prism software. The EC50 value of the compound was defined as the concentration required to stimulate luciferase activity to reach 50% in the presence of acetylcholine with EC20, and the results are provided as EC50 in Table 1B.
[0399] Table 1B: Allosteric Power EC50 Values of Muscarinic M4 Receptors
[0400]
[0401] Example 50: Rodent Pharmacokinetic Study
[0402] Male Wistar rats (250 ± 50 g) were used as experimental animals. The animals were housed individually in polypropylene cages. Two days prior to the study, male Wistar rats were anesthetized with isoflurane for surgical placement of a jugular venous catheter. The test compound was administered to the rats at a dose of 5 mg / kg and a dose volume of 2 mL / kg. The rats had free access to food and water during acclimatization, surgical recovery, and the study period.
[0403] The formulation for intraperitoneal administration was prepared using 5% v / v DMSO + 5% v / v Solutol HS15 + 90% v / v water for injection as the carrier. The dosage formulation was freshly prepared on the day of administration.
[0404] After administration, 200 μL of blood samples were collected via the jugular vein at each time point and compared with an equal volume of physiological saline.Saline supplementation. Collected blood samples were transferred to labeled Eppendorf tubes containing 10 μL of sodium heparin (1000 IU / mL) as an anticoagulant. Blood samples were collected at 0.08, 0.25, 0.5, 1, 2, 3, 5, 7, and 24 hours after administration. Blood was centrifuged at 4000 rpm for 10 minutes. Plasma was separated and frozen at -80°C until analysis. The concentration of the test compound in plasma was quantified using a suitable extraction technique and a qualified LC-MS / MS method. The study samples were analyzed using calibration samples (pages 48 / 50, CN 122003415 A) from the batch instructions and quality control samples distributed within the batch.
[0405] Pharmacokinetic parameters Cmax, Tmax, AUC0-t, and t1 / 2 were calculated using a standard non-compartmental model using Phoenix WinNonlin version 8.1 software. The pharmacokinetic profiles of the test compounds are shown in Table 2 below:
[0406] Table 2: Pharmacokinetic profiles of the compounds of the present invention
[0407]
[0408] Example 51: Antagonism of amphetamine-induced excitatory movement
[0409] Male Wistar rats weighing 230 to 250 g were used. The weight of the rats was recorded. The rats were randomly grouped according to their weight. The animals were brought to the laboratory 1 hour in advance to acclimatize to the laboratory conditions. The open field was a 51×51×51 cm black field enclosed by black plastic walls of the same size. The rats were allowed to acclimatize to the open field for a period of 30 minutes. Based on brain exposure, the animals were given the appropriate treatment (carrier or test compound). After the acclimatization period, the animals were challenged with amphetamine (0.5 mg / Kg, sc) or the carrier. The animals were then placed in the open field and the distance traveled by the rats was tracked using Videomotot software for 120 minutes. The data were analyzed using GraphPad Prism. The results of the test compounds are shown in Table 3 below:
[0410] Table 3: Antipsychotic-like activity of the compounds of the present invention
[0411]
[0412] Example 52: Receptor Occupancy Study in Rats
[0413] Male Wistar rats (250 ± 50 g) were used as experimental animals. The animals were housed alone in polypropylene cages and acclimatized to the experimental conditions for 4 days. On the day of the experiment, the carrier (10 mL / Kg) or the test compound (3, 10 or 30 mg / Kg) was administered intraperitoneally to the rats. At the Tmax of the test compound, 3 μg / Kg MK-6884 (tracer) was administered intravenously to all rats via the lateral tail vein. Five minutes after administration of the tracer, the rats were euthanized by cervical dislocation, the brain was separated from the skull, and the brain was placed on ice.The samples were splashed with cold water and the two brain regions (striatum and cerebellum) were separated and transferred to their respective pre-labeled / weighed microcentrifuge tubes and stored on dry ice or at -80°C until tracer extraction and analysis were performed using an LC-MS / MS-based method. The tracer concentration of the study samples was analyzed using calibration samples from the batch and quality control samples distributed in the batch.
[0414] Receptor occupancy in the striatum was calculated using a tracer-based ratio method.
[0415] Table 4: Receptor occupancy of the test compounds of the present invention Specification 49 / 50 pages 55 CN 122003415 A
[0416] Specification 50 / 50 pages 56 CN 122003415 A
Claims
1. A compound of formula (I), or an isotopic form or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, in, Each can be a single bond or a double bond independently; X1 is N or C, provided that R1 does not exist when X1 is N; X2, X3, X4, X5, and X6 are independently selected from N or C, provided that at least one of X2, X3, X4, X5, and X6 is C; and provided that R2, R3, or R4 does not exist when X4, X5, or X6 is N. R1, when present, is selected from hydrogen, halogen, cyano, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl or C1-C4 alkoxyalkyl; R2, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH or C1-C4 alkoxyalkyl; R3, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH or C1-C4 alkoxyalkyl; R4, when present, is selected from hydrogen, deuterium, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, -CH2OH or C1-C4 alkoxyalkyl; R5 is selected from hydrogen, halogen, -NH2, -NHCH3, C1-C4 alkyl, C1-C4 alkoxyalkyl, C3-C7 cycloalkyl, or C4-C 10 Heterocyclic alkyl groups; R6 is independently selected from hydrogen or C1-C4 alkyl; A is selected from 3 to 7-membered cycloalkyl or 4 to 10-membered heterocycloalkyl, wherein the cycloalkyl and heterocycloalkyl are optionally substituted by 1 to 5 substituents independently selected from hydrogen, halogen, deuterium, cyano, -OC1-C4 alkyl and C1-C4 haloalkyl; B is selected from 6- to 10-membered aryl or 5- to 10-membered heteroaryl, wherein the aryl and heteroaryl groups are optionally substituted by 1 to 5 substituents independently selected from hydrogen, deuterium, halogen, cyano, hydroxyl, -NH2, NHCH3, C1-C4 alkyl, C1-C4 haloalkyl, -OC1-C4 alkyl, -OC1-C4 haloalkyl, and C3-C7 cycloalkyl; and n is an integer between 0 and 3.
2. The compound of formula (I) according to the foregoing embodiments, or its isotopic form, stereoisomer, or pharmaceutically acceptable salt, wherein the compound is selected from: 1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; 1-(2,5-Dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone; 1-(2,5-Dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-acetone; 1-(2,5-Dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-4-yl-azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-chloro-5-methoxy-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5-dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-acetone; (2,5-Dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-methyl ketone; (2,5-Dimethyl-6,8-dihydro-1,3,7,8b-tetraaza-asymmetric indarsen-7-yl)-(1-pyridin-3-yl-pyrrolidine-3(R)-yl)-methyl ketone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-(1-pyridin-4-yl-azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-acetone; 1-(4,7-dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(3-trifluoromethyl-phenyl)-azacyclobutane-3-yl]-ethyl ketone; (4,7-Dimethyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-methyl ketone; 1-(4-methyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 1-(4-methyl-1,3-dihydro-2,6,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; 1-(4-methyl-1,3-dihydro-2,7,8a-triaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,5-dimethyl-6,8-dihydro-2,3a,7-triaza-asymmetric indarsen-7-yl)-acetone; 1-(4,5-dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4,5-Dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone; 1-(4,5-dimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(3,4,5-trimethyl-6,8-dihydro-1,2,3a,7-tetraaza-asymmetric indarsen-7-yl)-acetone; 1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(5,6-dimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; 2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; 2-(1-pyridin-3-yl-azacyclobutane-3-yl)-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(2,5,6-trimethyl-7,9-dihydro-pyrrolo[3,4-c][1,2,4]triazolo[1,5-a]pyridin-8-yl)-acetone; 1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; 1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone; 1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-1-(4,5-dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-acetone; (4,5-Dimethyl-6,8-dihydro-1,3a,7-triaza-asymmetric indarsen-7-yl)-[1-(2-trifluoromethyl-pyridin-4-yl)-pyrrolidine-3(R)-yl]-methyl ketone; 1-(5-methyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(6-trifluoromethyl-pyridin-3-yl)-azacyclobutane-3-yl]-acetone; 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(5-azacyclobutane-1-yl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-difluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(2-Methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; 1-(2-Methyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 1-(2,5-Dimethyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 1-(2,5-Dimethyl-6,8-dihydro-1,4,7,8b-tetraaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; 1-(4-methyl-1,3-dihydro-2,5,6,8a-tetraaza-asymmetric indarsen-2-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-ethyl ketone; 1-(4-methyl-1,3-dihydro-2,5,6,8a-tetraaza-asymmetric indarsen-2-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone; 1-(1,5-dimethyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-[1-(2-trifluoromethyl-pyridin-4-yl)-azacyclobutane-3-yl]-acetone; or 1-(1,5-dimethyl-6,8-dihydro-2,3,4,7,8b-pentaza-asymmetric indarsen-7-yl)-2-(1-pyridin-3-yl-azacyclobutane-3-yl)-ethyl ketone.
3. The compound of formula (I) according to claim 1 or claim 2, or its isotopic form, stereoisomer or pharmaceutically acceptable salt thereof, used as a positive allosteric modulator of muscarinic M4 receptor (M4 PAM).
4. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or claim 2, or an isotopic form, stereoisomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
5. The pharmaceutical composition according to claim 4, for treating diseases or disorders mediated by muscarinic M4 receptors, wherein the disease or disorder is selected from mental disorders, neurological disorders, pain disorders, sleep disorders, or cognitive disorders.
6. The compound of formula (I) according to claim 1 or claim 2, or its isotopic form, stereoisomer or pharmaceutically acceptable salt thereof, for the treatment of diseases or disorders mediated by muscarinic M4 receptors, wherein the diseases or disorders are selected from mental disorders, nervous system disorders, pain disorders, sleep disorders or cognitive disorders.
7. The compound of claim 6, wherein the mental disorder is selected from anxiety, personality disorder, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), bipolar disorder, attention deficit / hyperactivity disorder (ADHD), psychosis, schizophrenia, substance use disorder, and psychotic disorder.
8. The compound of claim 6, wherein the neurological disease or disorder is selected from Alzheimer's disease, Rett syndrome, Huntington's disease, vascular dementia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
9. The compound of claim 6, wherein the cognitive impairment is selected from amnesia, dementia, amnesic disorder, dementia due to Alzheimer's disease, dementia due to HIV, dementia due to Huntington's disease, dementia due to Parkinson's disease, Lewy body dementia, vascular dementia, frontotemporal dementia, senile dementia, dementia associated with Down syndrome, dementia associated with Tourette syndrome, dementia associated with postmenopausal syndrome, Kreutzfeldt-Jacob dementia, substance-induced persistent dementia, Pick's disease dementia, Huntington's disease dementia, traumatic brain injury, prions, HIV-related neurocognitive impairment, mild cognitive impairment, and any other disease with cognitive symptoms.
10. The compound of claim 7, wherein the schizophrenia is selected from schizophrenic cognitive impairment, positive symptoms of schizophrenia, and / or negative symptoms of schizophrenia.
11. The compound of claim 7, wherein the psychotic disorder is selected from psychosis associated with Alzheimer's disease, psychosis associated with Parkinson's disease, psychotic depression, psychosis associated with stroke, psychosis associated with epilepsy, psychosis associated with multiple sclerosis, psychosis associated with traumatic brain injury, substance-induced persistent delirium, or any other disease with psychotic characteristics.
12. Compounds of formula (II) or their pharmaceutically acceptable salts: in, Each can be a single bond or a double bond independently; X1 is selected from C or N; X2 is selected from C or N; X3 is selected from C or N; X4 is selected from C or N; X5 is selected from C or N; X6 is selected from C or N; The condition is that at least one of X1, X2, X3, X4, X5, and X6 is C; the condition is that if X1, X2, X3, X4, X5, or X6 is N, then R1, R2, R3, or R4 does not exist. R1, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C6 alkyl. 10 Heterocyclic alkyl groups; R2, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C 10 Heterocyclic alkyl groups; R3, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC. 1- C4 alkyl, C1-C4 haloalkyl, C3-C4 cycloalkyl or C4-C 10 Heterocyclic alkyl groups; R4, when present, is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C4. 10 Heterocyclic alkyl groups; R5 is selected from hydrogen, halogen, C1-C4 alkyl, -OC1-C4 alkyl, C1-C4 haloalkyl, C3-C7 cycloalkyl, or C4-C 10 Heterocyclic alkyl groups; and R6 is selected from hydrogen or C1-C4 alkyl.
13. The compound of formula (II) according to claim 12 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2 or CF3; wherein R2 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2 or CF3; wherein R3 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2 or CF3; wherein R4 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2 or CF3; wherein R5 is selected from hydrogen, chlorine, fluorine, methyl, ethyl, methoxy, ethoxy, CHF2, CF3 or R6 is selected from hydrogen, methyl, or ethyl.
